Superspecialty service guidelines for lung transplantation services

Australian Health Technology Advisory Committee
Record ID 31999009188
Authors' objectives:

To provide service delivery guidelines for lung transplant procedures.

Authors' recommendations: Lung transplantation offers the promise of improved survival and quality of life to selected people with life threatening lung diseases. There is a high degree of risk attached to the surgery and the post-operative course of treatment. However, the outlook for patients receiving transplants, regardless of the form - single, bilateral or heart-lung - has improved significantly, with the majority of patients, approximately 80 per cent, living at least a year or more following their transplant, and 60 per cent living four or more years. Developments in immunosuppressive drugs, in particular the discovery of Cyclosporin in 1976, have played a key role in transplantation technologies. The shortage of donor organs has led to interest in alternatives to whole lung transplantation. These are lobar lung transplantation from living donors, lung volume reduction surgery and xenotransplantation.
Authors' methods: Guideline, Review
Project Status: Completed
URL for project:
Year Published: 1998
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Costs and Cost Analysis
  • Immunosuppressive Agents
  • Lung Transplantation
Organisation Name: Australian Health Technology Advisory Committee
Contact Address: Naarilla Hirsch, Australian Institute of Health and Welfare Health Technology Unit, GPO Box 570, Canberra, ACT, 2601, Australia
Copyright: Australian Health Technology Advisory Committee
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.